FDA grants approval to Sanofi-Topaz Sklice treatment

The FDA have granted approval on Tuesday 7 February 2012 to Sklice® lotion, the ivermectin-based topical treatment produced by Topaz Pharmaceuticals, now part of Sanofi Pasteur US.

 The 0.5% ivermectin lotion, to be marketed as Sklice, will be available for patients of age 6 months or older. Phase III clinical trials confirmed that the treatment was safe and well-tolerated by prospective patients. The majority of patients tested were lice-free after two weeks following a single, 10-minute Sklice treatment.